Page 6 - BLADDER CANCER
P. 6

Enfortumab Vedotin






                • Antibody-drug conjugate


                       • Target is Nectin-4, highly expressed in urothelial carcinoma


                       • Monoclonal antibody and monomethyl auristatin E (MMAE)


                              • Microtubule disrupting agent





                • Clinical benefit previously demonstrated in phase I / II


                   studies


                       • Durable clinical responses noted
   1   2   3   4   5   6   7   8   9   10   11